PharmGen Science Inc Total Assets
PharmGen Science Inc total assets. Based on the latest financial reports, PharmGen Science Inc (004720) holds total assets worth ₩331.46 Billion KRW (≈ $224.63 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see PharmGen Science Inc market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of PharmGen Science Inc (2004–2024)
Total assets of PharmGen Science Inc from 2004 to 2024. This chart illustrates how PharmGen Science Inc's total assets have evolved over time, based on quarterly financial data. See 004720 live share price for real-time trading data and today's change.
PharmGen Science Inc - Asset Composition Analysis
PharmGen Science Inc Total Assets Breakdown (December 2024)
PharmGen Science Inc total assets breakdown as of December 2024. PharmGen Science Inc's total assets of ₩331.46 Billion consist of 30.5% current assets and 69.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 10.4% |
| Accounts Receivable | ₩39.30 Billion | 10.8% |
| Inventory | ₩31.84 Billion | 8.8% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩7.13 Billion | 2.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how PharmGen Science Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore PharmGen Science Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PharmGen Science Inc's current assets represent 30.5% of total assets in 2024, an increase from 0.0% in 2004.
- Cash Position: Cash and equivalents constituted 10.4% of total assets in 2024, up from 2.7% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 68.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 10.8% of total assets.
PharmGen Science Inc Competitors by Total Assets
Key competitors of PharmGen Science Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Cosmo Pharmaceuticals N.V
F:C43
|
Germany | €612.64 Million |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.71 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
PharmGen Science Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.25 | 1.62 | 1.99 |
| Quick Ratio | 1.44 | 1.17 | 1.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩52.14 Billion | ₩39.57 Billion | ₩37.21 Billion |
PharmGen Science Inc - Advanced Valuation Insights
This section examines the relationship between PharmGen Science Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.36 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 8.2% |
| Total Assets | ₩363.45 Billion |
| Market Capitalization | $42.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values PharmGen Science Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: PharmGen Science Inc's assets grew by 8.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for PharmGen Science Inc (2004–2024)
The table below shows the annual total assets of PharmGen Science Inc from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩363.45 Billion ≈ $246.31 Million |
+8.20% |
| 2023-12-31 | ₩335.92 Billion ≈ $227.65 Million |
+5.84% |
| 2022-12-31 | ₩317.39 Billion ≈ $215.09 Million |
+44.06% |
| 2021-12-31 | ₩220.32 Billion ≈ $149.31 Million |
+62.55% |
| 2020-12-31 | ₩135.54 Billion ≈ $91.86 Million |
+35.50% |
| 2019-12-31 | ₩100.03 Billion ≈ $67.79 Million |
+1.88% |
| 2018-12-31 | ₩98.19 Billion ≈ $66.54 Million |
+43.39% |
| 2017-12-31 | ₩68.48 Billion ≈ $46.41 Million |
+6.50% |
| 2016-12-31 | ₩64.30 Billion ≈ $43.58 Million |
+38.43% |
| 2015-12-31 | ₩46.45 Billion ≈ $31.48 Million |
+10.48% |
| 2014-12-31 | ₩42.04 Billion ≈ $28.49 Million |
+6.90% |
| 2013-12-31 | ₩39.33 Billion ≈ $26.65 Million |
-7.71% |
| 2012-12-31 | ₩42.61 Billion ≈ $28.88 Million |
-0.49% |
| 2011-12-31 | ₩42.82 Billion ≈ $29.02 Million |
-35.57% |
| 2005-12-31 | ₩66.47 Billion ≈ $45.04 Million |
+34.32% |
| 2004-12-31 | ₩49.49 Billion ≈ $33.54 Million |
-0.83% |
| 2004-09-30 | ₩49.90 Billion ≈ $33.82 Million |
-- |
About PharmGen Science Inc
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed i… Read more